$TSOI - Revised information about multiple business drivers for $TSOI in 2024... Exciting developments ahead!
1. Epilepsy Bio, Inc. struts in as the 9th subsidiary, with ALS Biologics following closely as the cool 8th kid on the block. And guess what? More siblings are joining the genetic party! 💪🧬
2. Orphan Drug Designation – because JadiCell Adult Stem Cells are not your average stem cells; they're the healing stars set to treat Frontotemporal Dementia and kick Acute Respiratory Distress Syndrome's butt. Currently knocking doors of the FDA – fingers crossed for the approval👍
3. TSOI's sub Allogen Biologics throws a science soirée with their Phase 3 ARDS trial, started the party in August 2023 and RSVPing for a grand finale in September 2024. 💪
4. Legal showdown alert! Restem Inc. and JadiCell LLC are duking it out in DC Federal Court, with Amici (submitted by Tim Dixon) 1.0 & 2.0 taking center stage. Meanwhile, the University of Miami is trying to hide from the embarrassing evidence of Phase 2 clinical trial shenanigans – but we see you! Validated and vindicated, mic drop! 🎤💥
5. TSOI's subsidiary, Campbell Neuro Sciences Inc (CNSI), is gearing up for a Nasdaq IPO extravaganza! Shareholders who opted for the free $.00358 CNSI dividend are gearing up grand party, as CNSI shares do the tango, going from $1 to $2 per share. Get ready for the Nasdaq debut – it's going to be a showstopper at $4 per share on Nasdaq Small Cap or $5 per share on NASDAQ (!!!) 🎉
6. Brace yourselves for a patent parade! $TSOI is about to unleash more in-house-developed patents - File, publish, issue – because history says so! 🎉
6. Treatment based on Right to Try (RTT) at Veltmeyer Institute (VIAB) is platform for groundbreaking treatments, bringing hope to the hopeless TODAY! It's not just a model; it's a phenomenal model – cue the standing ovation! 🙌
